Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Digoxin Dangers: A proportion of patients treated with digoxin, a cardiac glycoside used to treat heart function abnormalities, generate the inactive metabolite, dihydrodigoxin, resulting in poor efficacy. Haiser et al. (p. 295 ) examined a potential culprit responsible for this transformation—the actinobacterium, Eggerthella lenta —to probe the microbiota-digoxin interaction. Microbe growth was promoted by arginine, and differential expression analysis revealed a two-gene cardiac glycoside reductase ( cgr ) operon that was induced by digoxin in low arginine conditions. Not all strains of E. lenta could reduce digoxin and, when fecal samples from healthy people were tested, a spectrum of digoxin inactivation was detected. When the digoxin-reducing strain of E. lenta was given to germ-free mice that were fed a high-protein (that is, high-arginine) diet, digoxin levels stayed high in serum, and drug inactivation was suppressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Notably, the cgr ratio could be used to effectively discriminate microbial communities exhibiting low versus high digoxin reduction (Fig. 5).”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“The amino acid arginine prevents digoxin inactivation by E. lenta in vitro, decreasing the expression and activity of the genes responsible (the cgr operon)67.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“Because the intestine is a major site for drug metabolism (both by cytochrome P-450 enzymes in intestinal epithelial cells and by the gut microbiome87)”
From Microfluidic Organ-on-a-Chip Models of Human Intestine (2018) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Haiser et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“was inducible by the drug it metabolizes (Haiser et al., 2013).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Haiser et al., 2013
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer3—new capabilities and interfaces
Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B. C., Remm, M., & Rozen, S. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,461
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Versatile and open software for comparing large genomes
Kurtz, S., Phillippy, A., Delcher, A. L., Smoot, M., Shumway, M., Antonescu, C., & Salzberg, S. L. (2004) · Genome Biology · doi:10.1186/gb-2004-5-2-r12 · Cited by 5,254
Breitling, R., Armengaud, P., Amtmann, A., & Herzyk, P. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.055 · Cited by 1,496
Isolation of a Bacterium That Reductively Dechlorinates Tetrachloroethene to Ethene
Maymó-Gatell, X., Chien, Y.-T., Gossett, J. M., & Zinder, S. H. (1997) · Science · doi:10.1126/science.276.5318.1568 · Cited by 1,125
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
SSAHA: A Fast Search Method for Large DNA Databases
Ning, Z., Cox, A. J., & Mullikin, J. C. (2001) · Genome Research · doi:10.1101/gr.194201 · Cited by 965
Xenobiotics shape the physiology and gene expression of the active human gut microbiome
Maurice, C. F., Haiser, H. J., & Turnbaugh, P. J. (2013) · Cell · doi:10.1016/j.cell.2012.10.052 · Cited by 811
A Catalog of Reference Genomes from the Human Microbiome
The Human Microbiome Jumpstart Reference Strains Consortium, Nelson, K. E., Weinstock, G. M., Highlander, S. K., Worley, K. C., Creasy, H. H., Wortman, J. R., Rusch, D. B., Mitreva, M., Sodergren, E., et al. (2010) · Science · doi:10.1126/science.1183605 · Cited by 702
Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy
Lindenbaum, J., Rund, D. G., Butler, V. P., Tse-Eng, D., & Saha, J. R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110013051403 · Cited by 423
Cited by
The Human Intestinal Microbiome in Health and Disease
Lynch, S. V., & Pedersen, O. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1600266 · Cited by 3,637
The gut microbiome in atherosclerotic cardiovascular disease
Jie, Z., Xia, H., Zhong, S.-L., Feng, Q., Li, S., Liang, S., Zhong, H., Liu, Z., Gao, Y., Zhao, H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00900-1 · Cited by 1,638
The Integrative Human Microbiome Project
The Integrative HMP (iHMP) Research Network Consortium, Proctor, L. M., Creasy, H. H., Fettweis, J. M., Lloyd-Price, J., Mahurkar, A., Zhou, W., Buck, G. A., Snyder, M. P., Strauss, J. F., et al. (2019) · Nature · doi:10.1038/s41586-019-1238-8 · Cited by 1,381
Enterotypes in the landscape of gut microbial community composition
Costea, P. I., Hildebrand, F., Arumugam, M., Bäckhed, F., Blaser, M. J., Bushman, F. D., de Vos, W. M., Ehrlich, S. D., Fraser, C. M., Hattori, M., et al. (2017) · Nature Microbiology · doi:10.1038/s41564-017-0072-8 · Cited by 1,138
Mapping human microbiome drug metabolism by gut bacteria and their genes
Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., & Goodman, A. L. (2019) · Nature · doi:10.1038/s41586-019-1291-3 · Cited by 1,160
DRAM for distilling microbial metabolism to automate the curation of microbiome function
Shaffer, M., Borton, M. A., McGivern, B. B., Zayed, A. A., La Rosa, S. L., Solden, L. M., Liu, P., Narrowe, A. B., Rodríguez-Ramos, J., Bolduc, B., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa621 · Cited by 1,126
Diet dominates host genotype in shaping the murine gut microbiota
Carmody, R. N., Gerber, G. K., Luevano, J. M., Gatti, D. M., Somes, L., Svenson, K. L., & Turnbaugh, P. J. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2014.11.010 · Cited by 1,103
“Diet-induced changes in the gut microbiota could also alter key metabolic activities, as shown recently for the interaction between dietary protein and the bacterial inactivation of cardiac drugs (Haiser et al., 2013).”
BackgroundSelf-citationChemical transformation of xenobiotics by the human gut microbiota
Koppel, N., Maini Rekdal, V., & Balskus, E. P. (2017) · Science · doi:10.1126/science.aag2770 · Cited by 1,080
Self-citationStress and stability: applying the Anna Karenina principle to animal microbiomes
Zaneveld, J. R., McMinds, R., & Vega Thurber, R. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.121 · Cited by 977
Antibiotic-Induced Changes in the Intestinal Microbiota and Disease
Becattini, S., Taur, Y., & Pamer, E. G. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.04.003 · Cited by 901
“This activity is enhanced in the presence of other commensals, but is repressed by arginine, which can be supplemented through a high-protein diet [72].”
BackgroundThe Human Gut Microbiome: From Association to Modulation
Schmidt, T. S. B., Raes, J., & Bork, P. (2018) · Cell · doi:10.1016/j.cell.2018.02.044 · Cited by 845
“For example, specific strains of Eggerthella lenta have been shown to metabolize the cardiac drug digoxin, rendering it inefficient in some patients (Haiser et al., 2013).”
BackgroundTaur, Y., Jenq, R. R., Perales, M.-A., Littmann, E. R., Morjaria, S., Ling, L., No, D., Gobourne, A., Viale, A., Dahi, P. B., et al. (2014) · Blood · doi:10.1182/blood-2014-02-554725 · Cited by 885
Dietary metabolism, the gut microbiome, and heart failure
Tang, W. H. W., Li, D. Y., & Hazen, S. L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0108-7 · Cited by 789
Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., & Balskus, E. P. (2019) · Science · doi:10.1126/science.aau6323 · Cited by 753
Self-citationThe microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
Spanogiannopoulos, P., Bess, E. N., Carmody, R. N., & Turnbaugh, P. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.17 · Cited by 717
Self-citationSequencing and beyond: integrating molecular 'omics' for microbial community profiling
Franzosa, E. A., Hsu, T., Sirota-Madi, A., Shafquat, A., Abu-Ali, G., Morgan, X. C., & Huttenhower, C. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3451 · Cited by 719
Microbiome-wide association studies link dynamic microbial consortia to disease
Gilbert, J. A., Quinn, R. A., Debelius, J., Xu, Z. Z., Morton, J., Garg, N., Jansson, J. K., Dorrestein, P. C., & Knight, R. (2016) · Nature · doi:10.1038/nature18850 · Cited by 718
Gut microbiome interactions with drug metabolism, efficacy, and toxicity
Wilson, I. D., & Nicholson, J. K. (2017) · Translational Research · doi:10.1016/j.trsl.2016.08.002 · Cited by 656
Microfluidic Organ-on-a-Chip Models of Human Intestine
Bein, A., Shin, W., Jalili-Firoozinezhad, S., Park, M. H., Sontheimer-Phelps, A., Tovaglieri, A., Chalkiadaki, A., Kim, H. J., & Ingber, D. E. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.12.010 · Cited by 625
(2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.08.014 · Cited by 536
Deciphering microbial interactions in synthetic human gut microbiome communities
Venturelli, O. S., Carr, A. V., Fisher, G., Hsu, R. H., Lau, R., Bowen, B. P., Hromada, S., Northen, T., & Arkin, A. P. (2018) · Molecular Systems Biology · doi:10.15252/msb.20178157 · Cited by 544
Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents
Wang, X., Yang, S., Li, S., Zhao, L., Hao, Y., Qin, J., Zhang, L., Zhang, C., Bian, W., Zuo, L., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319766 · Cited by 541
Specialized metabolites from the microbiome in health and disease
Sharon, G., Garg, N., Debelius, J., Knight, R., Dorrestein, P. C., & Mazmanian, S. K. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.10.016 · Cited by 544
Effects of Psychological, Environmental and Physical Stressors on the Gut Microbiota
Karl, J. P., Hatch, A. M., Arcidiacono, S. M., Pearce, S. C., Pantoja-Feliciano, I. G., Doherty, L. A., & Soares, J. W. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02013 · Cited by 530
“Additional examples include tri-methylamine N-oxide, a metabolite derived from bacterial metabolism of dietary choline that has been linked to cardiovascular disease (Wang et al., 2014), and Eggerthella lenta, which plays an integral role in mediating effectiveness of the cardiac drug Digoxin (Haiser et al., 2013).”
BackgroundInfluentialCross-feeding in the gut microbiome: Ecology and mechanisms
Culp, E. J., & Goodman, A. L. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.03.016 · Cited by 504
Aguiar-Pulido, V., Huang, W., Suarez-Ulloa, V., Cickovski, T., Mathee, K., & Narasimhan, G. (2016) · Evolutionary Bioinformatics · doi:10.4137/ebo.s36436 · Cited by 499
Personalized Mapping of Drug Metabolism by the Human Gut Microbiome
Javdan, B., Lopez, J. G., Chankhamjon, P., Lee, Y.-C. J., Hull, R., Wu, Q., Wang, X., Chatterjee, S., & Donia, M. S. (2020) · Cell · doi:10.1016/j.cell.2020.05.001 · Cited by 474
“, digoxin reduction by Eggerthella lenta) (Haiser et al., 2013).”
BackgroundResultGut microbiota: A player in aging and a target for anti-aging intervention
Vaiserman, A. M., Koliada, A. K., & Marotta, F. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.01.001 · Cited by 465
Metagenome-wide association studies: fine-mining the microbiome
Wang, J., & Jia, H. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.83 · Cited by 429
Ananthakrishnan, A. N., Luo, C., Yajnik, V., Khalili, H., Garber, J. J., Stevens, B. W., Cleland, T., & Xavier, R. J. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.04.010 · Cited by 451
“An effect of the microbiome on therapy response has been demonstrated previously whereby inactivation of digoxin by Eggerthella lenta resulted in altered drug pharmacokinetics and reduced serum concentration(Haiser et al., 2013).”
BackgroundDe Filippis, F., Pasolli, E., Tett, A., Tarallo, S., Naccarati, A., De Angelis, M., Neviani, E., Cocolin, L., Gobbetti, M., Segata, N., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.01.004 · Cited by 397
Beyond gut feelings: how the gut microbiota regulates blood pressure
Marques, F. Z., Mackay, C. R., & Kaye, D. M. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.120 · Cited by 397
Molecular Networking As a Drug Discovery, Drug Metabolism, and Precision Medicine Strategy
Quinn, R. A., Nothias, L.-F., Vining, O., Meehan, M., Esquenazi, E., & Dorrestein, P. C. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.011 · Cited by 378
Poyet, M., Groussin, M., Gibbons, S. M., Avila-Pacheco, J., Jiang, X., Kearney, S. M., Perrotta, A. R., Berdy, B., Zhao, S., Lieberman, T. D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0559-3 · Cited by 376
Bacterial antagonism in host-associated microbial communities
García-Bayona, L., & Comstock, L. E. (2018) · Science · doi:10.1126/science.aat2456 · Cited by 373
“Antimicrobial toxins could also be used to selectively remove strains with pathogenic potential such as Clostrodium difficile, strains carrying resistance genes to clinically relevant antibiotics, and organisms associated with various drug failures such as to the cardiac drug digoxin (96) and cancer immunotherapies (9…”
BackgroundThe Role of the Gut Microbiota in the Relationship Between Diet and Human Health
Perler, B. K., Friedman, E. S., & Wu, G. D. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031522-092054 · Cited by 362
Vinarov, Z., Abdallah, M., Agundez, J. A. G., Allegaert, K., Basit, A. W., Braeckmans, M., Ceulemans, J., Corsetti, M., Griffin, B. T., Grimm, M., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105812 · Cited by 359
The Intestinal Metabolome: An Intersection Between Microbiota and Host
Ursell, L. K., Haiser, H. J., Van Treuren, W., Garg, N., Reddivari, L., Vanamala, J., Dorrestein, P. C., Turnbaugh, P. J., & Knight, R. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.001 · Cited by 355
Self-citationA Forward Chemical Genetic Screen Reveals Gut Microbiota Metabolites That Modulate Host Physiology
Chen, H., Nwe, P.-K., Yang, Y., Rosen, C. E., Bielecka, A. A., Kuchroo, M., Cline, G. W., Kruse, A. C., Ring, A. M., Crawford, J. M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.036 · Cited by 344
Advancing functional and translational microbiome research using meta-omics approaches
Zhang, X., Li, L., Butcher, J., Stintzi, A., & Figeys, D. (2019) · Microbiome · doi:10.1186/s40168-019-0767-6 · Cited by 340
“However, the extent of digoxin inactivation is also dependent on the presence of other gut microbes [118], indicating that a single biomarker using the presence of E.”
BackgroundIndividualized Medicine from Prewomb to Tomb
Topol, E. J. (2014) · Cell · doi:10.1016/j.cell.2014.02.012 · Cited by 333
“For example, even an individual’s response to medications, such as digoxin (Haiser et al., 2013), or multiple drugs used for cancer, has been shown to be linked to the bacterial flora of the gut microbiome (Viaud et al.”
Irritable bowel syndrome: A microbiome-gut-brain axis disorder?
Kennedy, P. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14105 · Cited by 331
The gut microbiome: an orchestrator of xenobiotic metabolism
Collins, S. L., & Patterson, A. D. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.001 · Cited by 348
Finding the Missing Links among Metabolites, Microbes, and the Host
Dorrestein, P. C., Mazmanian, S. K., & Knight, R. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.015 · Cited by 317
“…people have variable effects on the metabolism of drugs, ranging from the painkiller acetaminophen (Clayton et al., 2009) to the cardiac glycoside digoxin (Haiser et al., 2013) to the cancer drug cyclophosphamide (Viaud et al., 2013), and most likely also have an effect on immunomodulatory drugs.”
Gut microbiome, big data and machine learning to promote precision medicine for cancer
Cammarota, G., Ianiro, G., Ahern, A., Carbone, C., Temko, A., Claesson, M. J., Gasbarrini, A., & Tortora, G. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0327-3 · Cited by 324
Gut reactions: Breaking down xenobiotic–microbiome interactions
Clarke, G., Sandhu, K. V., Griffin, B. T., Dinan, T. G., Cryan, J. F., & Hyland, N. P. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.015768 · Cited by 319
“As detailed in Table 1, this can have consequences in terms of deactivating or activating drugs in the case of digoxin (Haiser et al., 2013) and sulfasala-zine (Peppercorn and Goldman, 1972b), respectively.”
BackgroundInfluentialMicrobiome therapeutics — Advances and challenges
Mimee, M., Citorik, R. J., & Lu, T. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.032 · Cited by 317
“Repression of this operon through supplementation of arginine or dietary protein can increase serum levels of active digoxin in mice [38].”
Schirmer, M., Denson, L., Vlamakis, H., Franzosa, E. A., Thomas, S., Gotman, N. M., Rufo, P., Baker, S. S., Sauer, C., Markowitz, J., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.09.009 · Cited by 293
“Microbial organisms also impact drug availability and treatment efficacy (Ananthakrishnan et al., 2017; Haiser et al., 2013; Sivan et al., 2015; Vetizou et al., 2015).”
BackgroundHuman gut microbiome aging clock based on taxonomic profiling and deep learning
Galkin, F., Mamoshina, P., Aliper, A., Lane, E., Moskalev, V., Gladyshev, V. N., & Zhavoronkov, A. (2020) · iScience · doi:10.1016/j.isci.2020.101199 · Cited by 292
Manipulating Bacterial Communities by in situ Microbiome Engineering
Sheth, R. U., Cabral, V., Chen, S. P., & Wang, H. H. (2016) · Trends in Genetics · doi:10.1016/j.tig.2016.01.005 · Cited by 290
Gut microbes may facilitate insect herbivory of chemically defended plants
Hammer, T. J., & Bowers, M. D. (2015) · Oecologia · doi:10.1007/s00442-015-3327-1 · Cited by 288
An integrative view of microbiome-host interactions in inflammatory bowel diseases
Wlodarska, M., Kostic, A. D., & Xavier, R. J. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.04.008 · Cited by 287
“Another important consideration in inflammatory disease is the impact of the microbiota on drug metabolism (Haiser et al., 2013; Maurice et al., 2013).”
BackgroundThe influence of gut microbiota on drug metabolism and toxicity
Li, H., He, J., & Jia, W. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1121234 · Cited by 278
“lenta 16S rDNA level) and ex vivo digoxin inactivation in healthy volunteers.[9] The elucidation of the mechanisms underlying the gut microbial metabolism on digoxin augments the understanding on gut microbial impacts on pharmacokinetics, and paves the way for clinical application of reducing drug toxicity by manipula…”
BackgroundDrug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
“The deactivation of digoxin is mediated by the transformation of digoxin to an inactivated state, dihydro-digoxin, by Eggerthella lenta ( E. 317 In another groundbreaking research, an operon coding for the E. lenta cytochrome, cardiac glycoside reductase (cgr), was identi fi ed to be…”
BackgroundHuang, Y. J., & Boushey, H. A. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.11.011 · Cited by 271
Watson, E., MacNeil, L. T., Ritter, A. D., Yilmaz, L. S., Rosebrock, A. P., Caudy, A. A., & Walhout, A. J. M. (2014) · Cell · doi:10.1016/j.cell.2014.01.047 · Cited by 268
“Altogether, themicrobiota facilitate digestion, affect xenobiotic response to drugs and other chemicals (Haiser et al., 2013; Maurice et al., 2013), and are critically important in the immunological defense (Kamada et al., 2013).”
BackgroundHost-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics
Carmody, R. N., & Turnbaugh, P. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72335 · Cited by 268
“This “cardiac glycoside reductase” ( cgr ) operon is present in the type strain of E. lenta but missing in other nonreducing E. lenta strains (20).”
Self-citationHost-microbe co-metabolism dictates cancer drug efficacy in C. elegans
Scott, T. A., Quintaneiro, L. M., Norvaisas, P., Lui, P. P., Wilson, M. P., Leung, K.-Y., Herrera-Dominguez, L., Sudiwala, S., Pessia, A., Clayton, P. T., et al. (2017) · Cell · doi:10.1016/j.cell.2017.03.040 · Cited by 254
“Similar mechanisms have been observed in mammals, where dietary arginine regulates the inactivation of the cardiac drug digoxin by the gut microbe E. lenta (Haiser et al., 2013).”
BackgroundMa, Z., Zuo, T., Frey, N., & Rangrez, A. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01946-6 · Cited by 259
“478 Similarly, Gardnerella vaginalis , the dominant bacterium in the vagina, can predict poor outcomes for tenofovir (a pre-exposure prophylactic drug for HIV infection), whereas Lactobacilli can increase its ef fi cacy threefold.”
BackgroundHuman gut bacterial metabolism drives Th17 activation and colitis
Alexander, M., Ang, Q. Y., Nayak, R. R., Bustion, A. E., Sandy, M., Zhang, B., Upadhyay, V., Pollard, K. S., Lynch, S. V., & Turnbaugh, P. J. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2021.11.001 · Cited by 260
Self-citationMicrobiome as a therapeutic target in alcohol-related liver disease
Sarin, S. K., Pande, A., & Schnabl, B. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.019 · Cited by 253
Taking it Personally: Personalized Utilization of the Human Microbiome in Health and Disease
Zmora, N., Zeevi, D., Korem, T., Segal, E., & Elinav, E. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2015.12.016 · Cited by 252
“A more recent study (Haiser et al., 2013) demonstrated that digoxin indeed undergoes inactivation by the species Eggerthella lenta and that the administration of antibiotics can offset this effect.”
BackgroundProteobacteria explain significant functional variability in the human gut microbiome
Bradley, P. H., & Pollard, K. S. (2017) · Microbiome · doi:10.1186/s40168-017-0244-z · Cited by 249
Microbiota-mediated inflammation and antimicrobial defense in the intestine
Caballero, S., & Pamer, E. G. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120238 · Cited by 238
“Recent studies have demonstrated, for example, that some strains of Eggerthella lenta, a member of the human microbiota, can inactivate the cardiac drug digoxin and that changes in diet can alter in vivo metabolism of the drug, leading to different drug levels (161).”
Microbiome-based interventions to modulate gut ecology and the immune system
Hitch, T. C. A., Hall, L. J., Walsh, S. K., Leventhal, G. E., Slack, E., de Wouters, T., Walter, J., & Clavel, T. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00564-1 · Cited by 243
The influence of the gut microbiota on the bioavailability of oral drugs
Zhang, X., Han, Y., Huang, W., Jin, M., & Gao, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.013 · Cited by 242
Emerging roles of the microbiome in cancer
Bultman, S. J. (2014) · Carcinogenesis · doi:10.1093/carcin/bgt392 · Cited by 239
A low-cost paper-based synthetic biology platform for analyzing gut microbiota and host biomarkers
Takahashi, M. K., Tan, X., Dy, A. J., Braff, D., Akana, R. T., Furuta, Y., Donghia, N., Ananthakrishnan, A., & Collins, J. J. (2018) · Nature Communications · doi:10.1038/s41467-018-05864-4 · Cited by 236
Metatranscriptome of human faecal microbial communities in a cohort of adult men
Abu-Ali, G. S., Mehta, R. S., Lloyd-Price, J., Mallick, H., Branck, T., Ivey, K. L., Drew, D. A., DuLong, C., Rimm, E., Izard, J., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-017-0084-4 · Cited by 233
“Culture-independent fecal microbial transcription has been used in only a few cases to date to identify causal mechanisms in health outcomes, such as strain-specific variation in Eggerthella lenta expression influencing the efficacy of cardiac therapy 11 .”
Multimodal interactions of drugs, natural compounds and pollutants with the gut microbiota
Lindell, A. E., Zimmermann-Kogadeeva, M., & Patil, K. R. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00681-5 · Cited by 228
A unified initiative to harness Earth's microbiomes
Alivisatos, A. P., Blaser, M. J., Brodie, E. L., Chun, M., Dangl, J. L., Donohue, T. J., Dorrestein, P. C., Gilbert, J. A., Green, J. L., Jansson, J. K., et al. (2015) · Science · doi:10.1126/science.aac8480 · Cited by 217
Human Gut Microbiota and Drug Metabolism
Pant, A., Maiti, T. K., Mahajan, D., & Das, B. (2023) · Microbial Ecology · doi:10.1007/s00248-022-02081-x · Cited by 212
Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation
Lee, J. R., Muthukumar, T., Dadhania, D., Taur, Y., Jenq, R. R., Toussaint, N. C., Ling, L., Pamer, E., & Suthanthiran, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122399 · Cited by 211
Human symbionts inject and neutralize antibacterial toxins to persist in the gut
Wexler, A. G., Bao, Y., Whitney, J. C., Bobay, L.-M., Xavier, J. B., Schofield, W. B., Barry, N. A., Russell, A. B., Tran, B. Q., Goo, Y. A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525637113 · Cited by 214
Pharmacomicrobiomics: a novel route towards personalized medicine?
Doestzada, M., Vila, A. V., Zhernakova, A., Koonen, D. P. Y., Weersma, R. K., Touw, D. J., Kuipers, F., Wijmenga, C., & Fu, J. (2018) · Protein & Cell · doi:10.1007/s13238-018-0547-2 · Cited by 210
“The underlying mechanism remained unclear, however, until the discovery of specific Eggerthella lenta strains in 2013 (Haiser et al., 2013).”
BackgroundFunctional and phylogenetic assembly of microbial communities in the human microbiome
Shafquat, A., Joice, R., Simmons, S. L., & Huttenhower, C. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.01.011 · Cited by 212
Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids
Klaassen, C. D., & Cui, J. Y. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065698 · Cited by 201
“Feeding mice a high-protein diet decreased the formation of dihydrodigoxin and increased the serum concentrations of the active form of digoxin (Haiser et al., 2013).”
BackgroundHaiser, H. J., Seim, K. L., Balskus, E. P., & Turnbaugh, P. J. (2014) · Gut Microbes · doi:10.4161/gmic.27915 · Cited by 197
“Remarkably, we found that increasing dietary protein significantly elevates both serum and urinary digoxin levels, and that this only occurs in mice colonized with the type strain, which is capable of reducing digoxin.(18) These results suggest that host diet might provide one avenue with which to tune the rate of mic…”
BackgroundInfluentialSelf-citationBeresford-Jones, B. S., Forster, S. C., Stares, M. D., Notley, G., Viciani, E., Browne, H. P., Boehmler, D. J., Soderholm, A. T., Kumar, N., Vervier, K., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.003 · Cited by 194
“Asmice are common models for preclinical pharmaceutical research, we leveraged the MGBC to examine the conservation status and taxonomic location of 34 experimentally validated drug metabolizing genes from the human gut microbiota (Haiser et al., 2013; Maini Rekdal et al., 2019; Ridlon et al., 2013; Zimmermann et al.,…”
MethodSharpton, S. R., Schnabl, B., Knight, R., & Loomba, R. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.010 · Cited by 194
“, 2017), digoxin (Haiser et al., 2013), and anti-integrin therapy (Ananthakrishnan et al.”
BackgroundAnother renaissance for bile acid gastrointestinal microbiology
Ridlon, J. M., & Gaskins, H. R. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00896-2 · Cited by 183
The gut microbiota and its interactions with cardiovascular disease
Xu, H., Wang, X., Feng, W., Liu, Q., Zhou, S., Liu, Q., & Cai, L. (2020) · Microbial Biotechnology · doi:10.1111/1751-7915.13524 · Cited by 186
Reddel, S., Del Chierico, F., Quagliariello, A., Giancristoforo, S., Vernocchi, P., Russo, A., Fiocchi, A., Rossi, P., Putignani, L., & El Hachem, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-41149-6 · Cited by 184
Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease
Mehta, R. S., Mayers, J. R., Zhang, Y., Bhosle, A., Glasser, N. R., Nguyen, L. H., Ma, W., Bae, S., Branck, T., Song, K., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02217-7 · Cited by 168
Self-citationExperimental design and quantitative analysis of microbial community multiomics
Mallick, H., Ma, S., Franzosa, E. A., Vatanen, T., Morgan, X. C., & Huttenhower, C. (2017) · Genome Biology · doi:10.1186/s13059-017-1359-z · Cited by 192
“For example, combining mouse models with a small cohort of 20 human subjects, Haiser and colleagues [111] built on decades of work linking Eggerthella lenta to inactivation of digoxin [112] to identify an operon that is expressed in a strain-specific manner in a subset of human microbiome carriers.”
BackgroundMeta'omic Analytic Techniques for Studying the Intestinal Microbiome
Morgan, X. C., & Huttenhower, C. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.049 · Cited by 173
Personalized Pharmacogenomics: Predicting Efficacy and Adverse Drug Reactions
Pirmohamed, M. (2014) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090413-025419 · Cited by 169
Vitamin B 12 modulates the transcriptome of the skin microbiota in acne pathogenesis
Kang, D., Shi, B., Erfe, M. C., Craft, N., & Li, H. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab2009 · Cited by 171
Mesnage, R., Teixeira, M., Mandrioli, D., Falcioni, L., Ducarmon, Q. R., Zwittink, R. D., Mazzacuva, F., Caldwell, A., Halket, J., Amiel, C., et al. (2021) · Environmental Health Perspectives · doi:10.1289/ehp6990 · Cited by 166
“Three of these strains have their reference sequences (LB2 = CIP A158; LB3 = CIP 71 : 38; LB5= CIP 103888) in the biobank of the Center de Ressources Biologiques Institut Pasteur (Paris, France), while the strain LB7 was described by Henri-Dubernet et al. (2008).”
Doherty, M. K., Ding, T., Koumpouras, C., Telesco, S. E., Monast, C., Das, A., Brodmerkel, C., & Schloss, P. D. (2018) · mBio · doi:10.1128/mbio.02120-17 · Cited by 165
“women (7), as well as cardiac drugs (8) and cancer treatments (9, 10) in murine models of disease.”
Psychotropics and the Microbiome: a Chamber of Secrets…
Cussotto, S., Clarke, G., Dinan, T. G., & Cryan, J. F. (2019) · Psychopharmacology · doi:10.1007/s00213-019-5185-8 · Cited by 163
ElRakaiby, M., Dutilh, B. E., Rizkallah, M. R., Boleij, A., Cole, J. N., & Aziz, R. K. (2014) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2014.0018 · Cited by 164
“(Haiser et al., 2013)”
InfluentialCommensal Gut Bacteria Convert the Immunosuppressant Tacrolimus to Less Potent Metabolites
Guo, Y., Crnkovic, C. M., Won, K., Yang, X., Lee, J. R., Orjala, J., Lee, H., & Jeong, H. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.084772 · Cited by 177
NSAID–Gut Microbiota Interactions
Maseda, D., & Ricciotti, E. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01153 · Cited by 159
Human microbiome signatures of differential colorectal cancer drug metabolism
Guthrie, L., Gupta, S., Daily, J. P., & Kelly, L. (2017) · npj Biofilms and Microbiomes · doi:10.1038/s41522-017-0034-1 · Cited by 180
Gutted! Unraveling the Role of the Microbiome in Major Depressive Disorder
Bastiaanssen, T. F. S., Cussotto, S., Claesson, M. J., Clarke, G., Dinan, T. G., & Cryan, J. F. (2020) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000243 · Cited by 159
Koh, A., Mannerås-Holm, L., Yunn, N.-O., Nilsson, P. M., Ryu, S. H., Molinaro, A., Perkins, R., Smith, J. G., & Bäckhed, F. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.07.012 · Cited by 174
Symbiosis as a General Principle in Eukaryotic EvolutionPreprint
Douglas, A. E. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016113 · Cited by 169
“…research, in the light of evidence that the activities of the gut microbiota can determine the half-life and metabolic fate of orally administered drugs, with clinically important implications for drug efficacy and toxicity (Haiser and Turnbaugh 2012; Holmes et al. 2012; Haiser et al. 2013).”
BackgroundA Metabolic Pathway for Activation of Dietary Glucosinolates by a Human Gut Symbiont
Liou, C. S., Sirk, S. J., Diaz, C. A. C., Klein, A. P., Fischer, C. R., Higginbottom, S. K., Erez, A., Donia, M. S., Sonnenburg, J. L., & Sattely, E. S. (2020) · Cell · doi:10.1016/j.cell.2020.01.023 · Cited by 165
“One of the few studies that report specific bacterial genes and mechanisms acting on bioactive plant molecules identified a cytochrome-encoding operon responsible for inactivation of the plant-derived cardiac drug digoxin by the gut bacterium Eggerthella lenta (Haiser et al., 2013).”
BackgroundGut microbiota modulates drug pharmacokinetics
Zhang, J., Zhang, J., & Wang, R. (2018) · Drug Metabolism Reviews · doi:10.1080/03602532.2018.1497647 · Cited by 161
“Pharmacokinetic studies using gnotobiotic mice revealed that dietary protein reduces the in vivo microbial metabolism of digoxin, with significant changes to drug concentration in the serum and urine (Haiser et al. 2013).”
Background
Metadata
- Authors
- Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J.
- Affiliations
- Harvard University (US)
- Corresponding author
- Turnbaugh, Peter J.
- Venue
- Science
- Published
- 2013-07-19
- Volume
- 341
- Issue
- 6143
- Pages
- 295-298
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3736355
- OpenAlex
- W2161185495
- Cited by
- 704
- References
- 25
- Citations by year
- 2026: 66 · 2025: 58 · 2024: 64 · 2023: 65 · 2022: 54 · 2021: 59 · 2020: 77 · 2019: 56 · 2018: 56 · 2017: 41 · 2016: 31 · 2015: 31 · 2014: 38 · 2013: 8
- FWCI
- 39.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (112991_1)
- National Institute of General Medical Sciences (P50GM068763)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034854)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Eggerthella lenta, digoxin, drug inactivation, gut microbiota, cytochrome P450, gnotobiotic mice, dietary protein, pharmacokinetics, cardiovascular drugs, human-microbe interactions
- MeSH terms
- Animals, Arginine, Cytochromes, Dietary Proteins, Digoxin, Feces, Germ-Free Life, Humans, Mice, Inbred Strains, Operon, Gene Expression Regulation, Bacterial, Actinobacteria, Gastrointestinal Tract, Mice, Metagenome, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.